C4 Therapeutics Advances Cemsidomide Trials, Expands Roche Partnership
Event summary
- C4 Therapeutics reported $268.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with a runway to the end of 2028.
- The company initiated a Phase 1b trial evaluating cemsidomide in combination with elranatamab in March 2026.
- C4 Therapeutics entered into a new collaboration agreement with Roche in April 2026, receiving a $20 million upfront payment.
- The Phase 2 MOMENTUM trial is on track to complete enrollment by the end of Q1 2027.
- C4 Therapeutics decided not to advance CFT8919, an EGFR L858R degrader, into the next phase of clinical development outside of Greater China.
The big picture
C4 Therapeutics is positioning cemsidomide as a potentially foundational treatment for multiple myeloma, leveraging targeted protein degradation science. The company's expanded partnership with Roche and ongoing clinical trials highlight its strategic focus on advancing innovative cancer therapies. With a strong cash position, C4 Therapeutics aims to deliver the next generation of targeted protein degrader medicines to patients.
What we're watching
- Clinical Development
- The pace at which cemsidomide combination trials progress will determine its potential as a foundational therapy for multiple myeloma.
- Financial Sustainability
- Whether C4 Therapeutics can maintain its cash runway through key value inflection points without additional funding.
- Strategic Partnerships
- How the Roche collaboration will impact the development of degrader-antibody conjugates and expand C4 Therapeutics' reach in cancer treatment.
Related topics